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PCardiac Contractility Modulation
Electrical Signals Improve Myocardial
Gene Expression in Patients With Heart Failure
Christian Butter, MD,* Sharad Rastogi, MD,† Hans-Heinrich Minden, MD,* Jürgen Meyhöfer, MD,*
Daniel Burkhoff, MD, PHD,‡ Hani N. Sabbah, PHD†
Bernau/Berlin, Germany; Detroit, Michigan; and New York, New York
Objectives The objective of this study was to test whether cardiac contractility modulation (CCM) electric signals induce
reverse molecular remodeling in myocardium of patients with heart failure.
Background Heart failure is associated with up-regulation of myocardial fetal and stretch response genes and down-
regulation of Ca2 cycling genes. Treatment with CCM signals has been associated with improved symptoms
and exercise tolerance in heart failure patients. We tested the impact of CCM signals on myocardial gene ex-
pression in 11 patients.
Methods Endomyocardial biopsies were obtained at baseline and 3 and 6 months thereafter. The CCM signals were deliv-
ered in random order of ON for 3 months and OFF for 3 months. Messenger ribonucleic acid expression was an-
alyzed in the core lab by investigators blinded to treatment sequence. Expression of A- and B-type natriuretic
peptides and -myosin heavy chain (MHC), the sarcoplasmic reticulum genes SERCA-2a, phospholamban and
ryanodine receptors, and the stretch response genes p38 mitogen activated protein kinase and p21 Ras were
measured using reverse transcription-polymerase chain reaction and bands quantified in densitometric units.
Results The 3-month therapy OFF phase was associated with increased expression of A- and B-type natriuretic peptides,
p38 mitogen activated protein kinase, and p21 Ras and decreased expression of -MHC, SERCA-2a, phospho-
lamban, and ryanodine receptors. In contrast, the 3-month ON therapy phase resulted in decreased expression
of A- and B-type natriuretic peptides, p38 mitogen activated protein kinase and p21 Ras and increased expres-
sion of -MHC, SERCA-2a, phospholamban, and ryanodine receptors.
Conclusions The CCM signal treatment reverses the cardiac maladaptive fetal gene program and normalizes expression of
key sarcoplasmic reticulum Ca2 cycling and stretch response genes. These changes may contribute to the clini-
cal effects of CCM. (J Am Coll Cardiol 2008;51:1784–9) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.036m
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Plarge number of patients with advanced heart failure (HF)
re refractory to optimal standard medical therapy. This has
iven rise to development and testing of a host of new
evice-based therapies (1). One recent and potentially
roadly applicable treatment under investigation is cardiac
ontractility modulation (CCM) electrical signals (2,3). The
CM signals are relatively high-voltage electrical impulses
pplied to the myocardium during the absolute refractory
eriod. These signals do not initiate a new contraction or
rom the *Heart Center Brandenburg in Bernau/Berlin, Bernau/Berlin, Germany;
Division of Cardiovascular Medicine, Henry Ford Health System, Detroit, Michi-
an; and ‡Columbia University, New York, New York. Supported, in part, by
esearch grants from Impulse Dynamics USA, Inc., and by the National Heart, Lung,
nd Blood Institute, #P01 HL074237-04. Dr. Burkhoff is an employee of Impulse
ynamics. Dr. Sabbah is a consultant to Impulse Dynamics.d
Manuscript received October 12, 2007; revised manuscript received December 21,
007, accepted January 15, 2008.odify activation sequence as is the case with other thera-
ies such as cardiac resynchronization therapy (4). Rather,
CM signals are intended to enhance systolic function of
he failing myocardium (5–8). Preliminary clinical studies
uggest that CCM signal therapy is safe and can also
mprove exercise tolerance and quality of life in patients
ith HF (3,9) without increasing myocardial oxygen con-
umption (10). Recent studies in experimental HF suggest
hat a novel mechanism underlying these effects is normal-
zed expression of genes known to be pathologically up- or
own-regulated in HF (8). The purpose of this study was to
est whether similar effects are present in patients with HF.
ethods
atients and study protocol. The present study included
ata from 11 patients. This was a substudy of a random-
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May 6, 2008:1784–9 Gene Expression with CCM Signal Therapyzed, double blind, multicenter, crossover study of CCM
ignal therapy in patients with ejection fraction 35%
nd New York Heart Association functional class II/III
ymptomatic HF despite optimal medical therapy con-
ucted at 15 hospitals in Europe and included 164
atients (the FIX-CHF-4 [Fix-Chronic Heart Failure–4]
tudy). The major exclusion criteria included atrial fibril-
ation, patient eligible for cardiac resynchronization ther-
py, peak VO2 10 ml/kg/min, hospitalization within 1
onth for acute exacerbation of HF, revascularization
ithin 1 month or acute myocardial infarction within 3
onths of study entry.
Qualifying patients were implanted with an Optimizer
ystem (Impulse Dynamics USA, Inc., Orangeburg, New
ork). Details of the system implant have been provided
reviously (10). Two weeks following implant, patients were
andomized to 3 months of CCM signal treatment (group
, ON, n  7) or to sham treatment with the device left off
group 2, OFF, n 4) (Fig. 1, phase I). Three months later,
atients crossed over to the opposite treatment for an
dditional 3 months (phase II). Protocol-specified clinical
ollow-up visits at 3 and 6 months included cardiopulmo-
ary stress test (peak VO2), Minnesota Living with Heart
ailure Questionnaire (MLHFQ) and 6-min walk test
6MW). Patients participating in the present substudy
nderwent right heart biopsies at baseline and at the end of
he 3- and 6-month treatment periods. Samples were snap
rozen, stored in liquid nitrogen, and sent to a core lab that
as blinded to study sequence. Messenger ribonucleic acid
RNA) expression of glyceraldehyde-3-phosphate de-
ydrogenase, -myosin heavy chain (MHC), A- and B-
ype natriuretic proteins, sarcoplasmic reticulum calcium
denosine triphosphatase (SERCA-2a), phospholamban,
Figure 1 FIX-CHF-4 Study Design
This was a prospective, randomized, double-blind,
double crossover study. FIX-CHF-4  Fix-Chronic Heart Failure–4. F
dnd ryanodine receptor (RyR2),
odium-calcium exchanger, and
he stretch receptor genes p38
itogen activated protein kinase
nd p21 Ras were measured. De-
ails of the methods of isolation
nd analysis are identical to those
eported previously (11,12).
and intensity of each gene was
xpressed as a percent of the
ntensity of the respective gene at
aseline.
Data are expressed as mean
standard deviation. Data
rom this crossover study were
nalyzed according to the
ethods of Fleiss (13). In brief,
fter confirming the absence of
treatment-by-period interaction (by repeated measures
nalysis of variance), mean end-of-period values for ON
nd OFF periods are pooled and analyzed by paired t test.
orrelations between clinical outcome data and changes
n gene expression were performed by linear regression
nalysis.
The main study and the substudy were each approved by
he local ethics committee. Written informed consent was
btained from all patients prior to entry.
esults
linical characteristics. Patient baseline characteristics are
ummarized in Table 1. All patients were Caucasian men
ith New York Heart Association functional class III
ymptoms despite treatment with beta-blockers, angioten-
in converting enzyme inhibitors, or angiotensin receptor
lockers and, with one exception, spironolactone. Seven of
aseline Clinical Characteristics
Table 1 Baseline Clinical Characteristics
Group 1 Group 2 Overall
n 7 4 11
Age (yrs) 63 10 63 10 63 9
% male 100 100 100
Idiopathic/ischemic 5/2 2/2 7/4
% NYHA functional class III 100 100 100
EF (%) 26 4 30 7 28 6
QRS (ms) 125 14 122 28 124 19
HR (beats/min) 70 10 80 18 74 13
SBP (mm Hg) 107 11 106 17 107 13
MLHFQ 43 20 28 14 37 19
6MW (m) 458 88 436 85 450 83
Peak VO2 (ml O2/kg/min) 13.8 2.5 13.2 21 13.6 2.6
dP/dtmax (mm Hg/s) 860 94 921 134 881 108
dP/dtmax (%) 13 4 12 5 13 4
P/dtmax  peak positive rate of change of left ventricular pressure measured during Optimizer
ystem implant; EF  ejection fraction; HR  heart rate; MLHFQ  Minnesota Living with Heart
Abbreviations
and Acronyms
CCM  cardiac
contractility modulation
DNA  deoxyribonucleic
acid
HF  heart failure
MHC  myosin heavy chain
MLHFQ  Minnesota Living
with Heart Failure
Questionnaire
RNA  ribonucleic acid
SERCA-2a  sarcoplasmic
reticulum calcium
adenosine triphosphatase
6MW  6-min walk testailure Questionnaire; NYHA  New York Heart Associatio
uration; SBP  systolic blood pressure; 6MW  6-min wn functional classification; QRS  QRS
alk test.
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Gene Expression with CCM Signal Therapy May 6, 2008:1784–9he patients were randomized to group 1 (CCM signal
reatment during the first 3 months), and 4 patients were
andomized to group 2 (placebo during the first 3 months).
he groups were reasonably well-balanced with regard to
ther characteristics.
The MLHFQ scores averaged 23  14 at the end of ON
reatment periods compared with 35  17 at the end of
FF treatment periods (p  0.08). The 6MW averaged
53  97 m at the end of ON treatment periods compared
ith 402  111 m at the end of OFF treatment periods
p  0.27). Finally, peak VO2 averaged 14.5  4.3 ml
2/kg/min at the end of ON treatment periods compared
ith 11.9  3.8 ml O2/kg/min at the end of OFF treatment
eriods (p  0.15). Because of the small number of patients
nd large standard deviations, none of these differences was
tatistically significant.
ene expression. Typical Northern blots obtained from 1
roup 1 and 1 group 2 patient are shown in Figure 2. The
onsistent intensity of the glyceraldehyde-3-phosphate de-
ydrogenase band signifies consistent messenger RNA
oading between samples. Each panel shows the respective
and at baseline, 3 months, and 6 months. Genes that are
verexpressed in HF tended to decrease toward normal
uring CCM signal treatment, whereas genes that are
nderexpressed in HF tended to increase toward normal
uring CCM signal treatment. A detailed analysis of the
-MHC blots is shown in Figure 3. Band intensities were
Figure 2 Representative Northern Blots
Representative Northern blots from 2 patients, 1 from each treatment group. Diffe
The GAPDH band intensities show consistency of ribonucleic acid loading of the va
uretic peptides; CCM  cardiac contractility modulation; GAPDH  glyceraldehyde-
RAS  p21 Ras stretch receptor gene; p38MAPK  p38 mitogen activated protein
reticulum calcium adenosine triphosphatase.ormalized to their respective values obtained in the base-
ine heart failure state. Data from patients with ischemic
nd idiopathic cardiomyopathy are shown with dashed and
olid lines, respectively. At the end of phase I, -MHC
xpression increased in group 1 patients (device ON) (Fig.
A) and stayed the same or decreased in group 2 patients
device OFF) (Fig. 3B). After crossover, expression de-
reased in group 1 patients when the device was switched off
nd increased in group 2 patients when the device was
witched on. The overall comparisons are summarized in
anel C where results from ON periods are pooled and
esults from OFF periods are pooled. As shown, there was
statistically significant 62.7  45.3% increase in
-MHC expression above the HF baseline state in response
o CCM signal treatment. As shown in this typical example,
here was no substantive difference in the response identified
n hearts with idiopathic and ischemic cardiomyopathies.
Results from the other genes examined are summarized in
igure 4. There were statistically significant changes during
he ON periods in all genes examined compared to the
aseline HF state. The SERCA-2a, phospholamban, and
yR2 (genes whose expression is decreased in chronic HF)
ll increased in response to 3 months of CCM signal treat-
ent. A- and B-type natriuretic peptides, p38 mitogen
ctivated protein kinase, p21 Ras, and sodium-calcium
xchanger (genes whose expression is increased during
in band intensities between periods of active and sham treatment are evident.
lanes. ANP  A-type natriuretic peptides; BL  baseline; BNP  B-type natri-
phate dehydrogenase; MHC  myosin heavy chain; PLB  phospholamban; p21
e stretch receptor gene; RyR2  ryanodine receptor; SERCA-2a  sarcoplasmicrences
rious
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May 6, 2008:1784–9 Gene Expression with CCM Signal Therapyhronic HF) all decreased in response to 3 months of CCM
ignal treatment.
linical-molecular correlations. We explored correlations
etween changes in gene expression and clinical effects.
pecifically, we correlated percent changes in expression of
ERCA-2a and percent changes in peak VO2, MLHFS,
nd 6MW. These calculations were made by comparing
-month data to baseline and also comparing 6- to 3-month
ata (Fig. 5). Despite the small number of patients, there
ere statistically significant correlations between changes in
eak VO2 and MLHFQ and the change in SERCA-2a
xpression. The correlation between SERCA-2a and 6MW
Figure 3 -MHC Gene Expression
Changes in -myosin heavy chain (MHC) gene expression (quantified as percent of
Data summarized by pooling of the end of ON periods from the 2 groups and end
cardiomyopathy, whereas dashed lines are from patients with ischemic cardiomyo
Figure 4 Summary of Impact of CCM Signal Treatment on Gene
Summary of impact of cardiac contractility modulation (CCM) signal treatment on e
each gene analyzed as summarized in text and in the legend of Figure 3. NCX  sas not significant. These findings were similar for ischemic
nd idiopathic cardiomyopathy.
iscussion
e show that 3 months of CCM signal treatment is
ssociated with improved expression of genes that are either
bnormally down- or up-regulated in HF. No differences
ere identified in these responses in ischemic and idiopathic
ardiomyopathies. Because no tissue samples were available
rom normal controls, all changes are reported relative to the
aseline HF state. Therefore, it was not evaluated whether
ine) at the end of study periods in group 1 (A) and group 2 (B) patients. (C)
periods from the 2 groups. Solid lines show data from patients with idiopathic
ression
sion of genes examined in this study. Data for
-calcium exchanger; other abbreviations as in Figure 2.basel
of OFF
pathy.Exp
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Gene Expression with CCM Signal Therapy May 6, 2008:1784–9ene expression was normalized by CCM signal treatment,
ust that it improved toward the normal state. These
ndings are complementary to recently reported (8) effects
f chronic CCM signal treatment in experimentally induced
F in dogs. It is noteworthy that, as in the prior experi-
ental study, the clinical and molecular effects are identified
n patients already taking chronic beta-blocker therapy.
Early studies of the mechanisms underlying the acute
ffects of CCM signals focused on their impact on action
otential (5), peak intracellular calcium (2,14), and calcium
oading of the sarcoplasmic reticulum. The increase in
alcium was assumed to be the mechanism of increased
ontractility. More recent studies have suggested that CCM
Figure 5 Correlations Between Gene Expression
and Clinical Impact of CCM Signal Treatment
Percent changes in SERCA-2a expression were correlated with percent changes
in peak VO2 (A), Minnesota Living With Heart Failure Questionnaire (MLWHFQ)
(B), and 6-min walk test (6MW) (C). Data included comparison of results from
baseline to 3 to 6 months. DCM  idiopathic dilated cardiomyopathy; ICM 
ischemic cardiomyopathy; other abbreviations as in Figure 2.ignals can have an impact on gene expression and phos- mhorylation of key proteins (e.g., phospholamban) involved
ith calcium cycling and other basic aspects of cell function
ithin hours of signal application (8,15). The results of the
resent study extend these prior findings by showing they
re relevant to diseased human myocardium. These findings
re interesting in light of prior basic research showing that
ow frequency, low intensity electromagnetic fields can
nduce gene expression and modify enzymatic reactions
such as protein phosphorylation) within minutes in in vitro
ystems (16). It has been suggested that electromagnetic
elds accelerate electron transfer reactions that could in turn
timulate transcription by interacting with electrons in
NA to destabilize the hydrogen bonds holding the 2
NA strands together.
However, rather than invoking a direct effect of CCM
ignal treatment on gene expression, it is also possible that
he changes in gene expression are secondary to alleviation
f mechanical stresses brought about by local and global
hanges in myocardial function. For example, decreases in
- and B-type natriuretic peptides, p21 Ras, and p38
itogen activated protein kinase are typically interpreted as
ndicating reduced mechanical stresses. Thus, alleviating
xcessive myocardial stretch may be responsible for down-
egulation of stretch response proteins and block an impor-
ant signaling pathway for HF progression. Nevertheless, it
ust be acknowledged that the mechanisms of action and
he link between changes in gene expression and clinical
ffects are not clarified.
tudy limitations. The main limitation of the present study
s the small number of patients, which is due to the invasive
ature of the techniques required. Nevertheless, the correla-
ions between changes in myocardial gene expression and
unctional status indexed by either MLHFQ or peak VO2 were
f great interest. Although these findings are provocative, it
ould be premature to suggest any mechanistic link given the
imited data available at this time. The present study was also
imited to an evaluation of tissue sampled from the right
entricular septum in the region where CCM signals are
pplied, leaving open the question if the results would extend
o the left ventricle. In the prior animal study (8), CCM-
ediated changes in gene expression were present in the region
f signal application for the first several hours and present
lobally within 3 months. Because left heart biopsy was not
ossible, we cannot confirm that the changes identified would
lso be present in the remote areas of the myocardium. Also,
ecause of the relatively small amount of tissue available from
n endomyocardial biopsy, analysis of protein content and
unction were not possible. In our prior animal study (17),
here abundant amounts of tissue were available, messenger
NA expression, protein content, and protein function were
ll assessed.
onclusions
pplication of CCM signals to the failing heart for 3
onths is associated with improved expression of genes
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May 6, 2008:1784–9 Gene Expression with CCM Signal Therapyssociated with excitation-contraction coupling, and de-
reased expression of genes is associated with myocardial
tress. These findings are present in tissue from patients
ith HF of either ischemic or nonischemic etiology. Both of
hese findings are indicative of beneficial molecular reverse
emodeling. These findings are complementary to recent
ndings of the impact of CCM signals on gene expression
n experimental HF (8). These findings can be extended to
ailing human myocardium. However, the mechanisms by
hich CCM signal treatment has an impact on gene
xpression are not known. It is clear that if CCM signal
reatment improves myocardial stress on local and global
evels, secondary normalization of gene expression can
ccur. As discussed previously (17), however, direct (pri-
ary) effects cannot be excluded. A randomized clinical
rial, currently underway in the U.S., is designed to defin-
tively test the safety and efficacy of this form of novel
lectrical therapy for chronic advanced HF.
cknowledgment
he authors are grateful to Ms. Jana Hoffman for her
ssistance with data collection.
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